title: ErbB-targeted CAR T-cell immunotherapy of cancer.
abstract: Chimeric antigen receptor (CAR) based immunotherapy has been under development for the last 25 years and is now a promising new treatment modality in the field of cancer immunotherapy. The approach involves genetically engineering T cells to target malignant cells through expression of a bespoke fusion receptor that couples an HLA-independent antigen recognition domain to one or more intracellular T-cell activating modules. Multiple clinical trials are now underway in several centers to investigate CAR T-cell immunotherapy of diverse hematologic and solid tumor types. The most successful results have been achieved in the treatment of patients with B-cell malignancies, in whom several complete and durable responses have been achieved. This review focuses on the preclinical and clinical development of CAR T-cell immunotherapy of solid cancers, targeted against members of the ErbB family.
authors: King's College London, King's Health Partners Integrated Cancer Center, Department of Research Oncology, Guy's Hospital Campus, Great Maze Pond, London SE1 9RT, UK.
authors: Lynsey M
authors: LM
authors: Whilding
authors: John
authors: J
authors: Maher
mesh_terms: D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000235:genetics / Q000276:immunology*; D005818:Genetic Engineering; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008213:Lymphocyte Activation; D009369:Neoplasms / Q000628:therapy*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology*; D037182:T-Cell Antigen Receptor Specificity / Q000235:genetics / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology* / Q000637:transplantation
chemical_list: D011948:Receptors, Antigen, T-Cell; D011993:Recombinant Fusion Proteins; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: ErbB receptors; HER2; T cells; cancer; chimeric antigen receptor; immunotherapy